“Our analysis indicates that the first month of a patient receiving immune checkpoint inhibitor therapy is the crucial period for determining patients' risk of myocarditis fatality. If a patient… develops myocarditis in those first 30 days, that's a flashing warning light. This gives clinicians an actionable time frame for determining for whom [ICI] therapy may be dangerous.”
Kwan et al. (Sun,) studied this question.